BAM15 – Comprehensive Research Overview (2026)
BAM15 is a synthetic small-molecule mitochondrial protonophore (uncoupler) researched primarily for obesity, insulin resistance, fatty liver disease, and sarcopenia. Unlike classical uncouplers such as DNP, BAM15 selectively targets the inner mitochondrial membrane without affecting the plasma membrane, producing a favorable safety profile. It acts as an exercise-mimetic by increasing mitochondrial energy expenditure without requiring caloric restriction or physical activity.
→ View BAM15 (for laboratory research use only)
Mechanism of Action
- Selectively dissipates the mitochondrial proton gradient (uncoupling), forcing cells to burn more fuel (glucose and fat) to maintain ATP production.
- Increases basal metabolic rate and fat oxidation without stimulating the CNS or affecting plasma membrane potential.
- Reduces mitochondrial ROS production as a secondary effect of uncoupling.
- Improves insulin sensitivity by reducing lipid accumulation in muscle and liver.
Clinical Evidence and Research Findings
Preclinical studies in diet-induced obese mice demonstrate significant reductions in body fat, improved insulin sensitivity, and reduced liver fat without muscle loss or toxicity. BAM15 does not cause hyperthermia at effective doses (a key safety advantage over DNP). No human clinical trials have been published as of April 2026, but it remains one of the most promising exercise-mimetic compounds in preclinical research.
→ Interested in researching BAM15? View Product Options
Benefits (Research & Clinical Observations)
- Significant fat loss without caloric restriction
- Improved insulin sensitivity and glucose metabolism
- Reduced hepatic steatosis (liver fat)
- Preserved or improved muscle mass (unlike many weight-loss agents)
- No hyperthermia at effective doses
Typical Dosing Protocols (Preclinical)
- Preclinical mouse studies: ~4–10 mg/kg orally or by injection
- Human equivalent dosing not established; no approved clinical protocols
Safety Profile
Favorable preclinical safety profile with selective mitochondrial targeting. No plasma membrane effects, no hyperthermia, no significant organ toxicity at effective doses in animal models. Human safety data are not available.
BAM15 vs SLU-PP-332 vs MOTS-c – Quick Comparison
| Aspect | BAM15 | SLU-PP-332 | MOTS-c |
|---|---|---|---|
| Mechanism | Mitochondrial uncoupling | ERRα/β/γ pan-agonist | AMPK activation / mitochondrial peptide |
| Primary Effect | Increased energy expenditure | Exercise gene program activation | Insulin sensitivity & metabolic flexibility |
| Human Data | None | None | Phase 1 safety confirmed |
| FDA Status | Not approved | Not approved | Not approved |
Summary
BAM15 is a highly selective mitochondrial uncoupler with compelling preclinical evidence for fat loss, insulin sensitization, and liver fat reduction without the toxicity of classical uncouplers. It represents a promising exercise-mimetic approach to metabolic disease research. As with all compounds in this library, BAM15 is not an approved drug and should only be considered under qualified research supervision.
For Laboratory Research Use View BAM15 →
Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.